Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,308 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05190991RecruitingPhase 2
RPH-104 to prevent repeat fevers in colchicine-resistant FMF
This Phase 2 study tests whether RPH-104 can help prevent recurrent fever attacks in adults with Familial Mediterranean Fever (FMF) who cannot tolerate colchicine or whose disease does not respond to it. Participants may receive the medicine at the clinic or learn to give it as a self-injection, depending on what fits your situation.
YerevanAges 18–80 - NCT07564232RecruitingPhase 1
LNK001 for Advanced Kidney Cancer After Prior Treatments
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Houston, TexasAges 18 years+ - NCT06735495RecruitingPhase 1/Phase 2
Two-target CAR T cells for relapsed B-cell blood cancers
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Wuhan, HubeiAges 3–75 - NCT06731699RecruitingPhase 1
Testing FD-001 for blood cancers that returned or didn't respond
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
Chengdu, SichuanAges 18–80 - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+ - NCT07551050Recruiting
Sacituzumab Govitecan for Advanced HER2-Negative Breast Cancer
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07545967RecruitingPhase 1
Re-radiation and Chidamide for Recurrent Head and Neck Cancer
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT07549958RecruitingPhase 1
Gemcitabine with or without Pitavastatin for Advanced Pancreatic Cancer
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Orange, CaliforniaAges 18 years+ - NCT06689540RecruitingPhase 1
MTS105 for advanced liver cancer with GPC3
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
BeijingAges 18 years+ - NCT07535112RecruitingPhase 1
Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT07542600Recruiting
Spa therapy to help women with infertility after embryo transfer
This study tests whether spa-based rehabilitation—including thermal water treatments and relaxation therapies—may improve fertility outcomes in women who have had unsuccessful embryo transfers. Researchers hope it might help prepare the body for pregnancy.
Františkovy Lázně, Carlsbad RegionAges 20–40 - NCT07542080Recruiting
Comparing Two Surgical Approaches for Recurring Bladder Leakage
This pilot study compares two different surgical techniques to treat stress urinary incontinence (leaking urine when you cough, sneeze, or exercise). Researchers want to see which approach works better for women whose leakage has returned after previous treatment.
LondonAges 18–100 - NCT07542496Recruiting
Real-world study of breast cancer treatment with pertuzumab biosimilar
This study observes how a biosimilar version of pertuzumab (a targeted breast cancer drug) works in real-world patients. Researchers will track outcomes in patients receiving this drug either before surgery or as a first treatment for advanced breast cancer.
AlgiersAges 19 years+ - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT05709249RecruitingPhase 3
Chinese herbal medicine to help prevent colon cancer return
This Phase 3 study tests whether a Chinese herbal “decoction” (called XLJDOD) given after surgery and chemo can lower the chance that colon cancer comes back. It may help people with higher-risk colon cancer (Stage IIIB or IIIC) stay cancer-free longer.
NanjingAges 20–80 - NCT07533942RecruitingPhase 2
Testing JZP3507 for Recurrent Grade 2 or 3 Brain Tumors
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT07528183RecruitingPhase 2
Immunotherapy after chemo and radiation for recurrent nose cancer
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
Fuzhou, FujianAges 18–70 - NCT07519564RecruitingPhase 1
Study of GB18 Injection for Cancer-Related Weight Loss
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07521137RecruitingPhase 2
Biweekly occidiofungin for recurring yeast infections
This study tests occidiofungin, a new antifungal medication inserted into the vagina twice a week to prevent recurring yeast infections (vulvovaginal candidiasis). The goal is to see if this treatment can stop yeast infections from coming back.
Birmingham, AlabamaAges 18–65 - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT07524114Recruiting
Blood test to find leftover cancer after treatment
This study uses a blood test to look for tiny bits of cancer DNA after you finish treatment. It may help doctors know if cancer is still there and guide next steps.
Toronto, OntarioAges 18 years+ - NCT07522879RecruitingPhase 2
Testing a new drug combo for recurrent sinus cancer
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
ShanghaiAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,308 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.